Your physician will refer you to Gabbi if you could benefit from their services
to reduce the risk of sustained estimated GFR (eGFR) decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Ozempic and Rybelsus tablets: To reduce the risk of major CV events in patients with type 2 diabetes mellitus who are at high risk for these events Wegovy (injection and tablets): In combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse CV events in patients with established CV disease and either obesity or overweight Usual Adult Dose for Renal Risk Reduction Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: After at least 4 weeks on the 0.5 mg dose, increase to 1 mg subcutaneously once a week
Many patients report feeling less confident in their appearance, despite being healthier overall
DOI: Kayal M, Lambin T, Plietz M, et al
Helping you eat right and stay active An estimated one in three American adults are obese
Principal component analysis (PCA) and clustering heatmaps were performed using R (version 4.5.0)
